Many "normal" healthy volunteers will have abnormal ECGs or have abnormal ECGs which they are aware of. These abnormal ECGs may have a big impact on the development of a new chemical entity if the data obtained is not scrutinised properly at an early stage.
Early signal detection and full follow up by Richmond Pharmacology's cardiology team is essential to ensure that the digital ECG data obtained from an early phase trial is analysed and reported appropriately. Richmond Pharmacology has the capacity to undertake and subsequently analyse several cardiological assessments to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.
Analysis services include rest and exercise ECG analysis, detailed digital QT analysis, entry criteria validation, cardiac event classification and Holter provision, analysis and review. The assessments are performed using Richmond's bespoke and integrated MUSE setup.
We ensure rapid and reliable digital ECG data is obtained to support the “go” or “no-go” decisions during your early phase trial.
Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.
We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.